|
Gregory P. Licholai, M.D., M.B.A.
Dr. Licholai is a Consultant at McKinsey & Company. He has experience in serving
healthcare providers as well as biotechnology and pharmaceutical companies. Greg has
worked on strategic planning and operations transformations for providers of healthcare
services. He also has worked on commercial strategy for major biotechnology and
pharmaceutical companies. Prior to joining McKinsey he was engaged in healthcare
service and product development consulting and had several private equity firms as
clients.
Dr. Licholai has been an entrepreneur and executive in the biopharmaceutical industry. He was
Chief Operating Officer at Proteostasis, a private biotechnology company in Cambridge,
MA. Earlier, he had been one of the first employees at Amicus Therapeutics and helped
take the company public in 2007. He helped move the company from 10 to over 150
employees and raise private and public funds. He was also co-founder of Immunome, Inc
a biotechnology firm focused on a novel antibody platform. He was a venture capitalist
at Domain Associates based in Princeton, NJ. Previously he was director of Ventures
and Business Development at Medtronic Neurological. Greg trained at the Brigham
and Women's, Children's, and Massachusetts General Hospitals. He was a Howard
Hughes Medical Institute Research Scholar at the National Institutes of Health. He did
research in molecular genetics at Yale University and examined variants in hereditary
blood diseases. He also worked in molecular oncology at Rockefeller University. Greg
received his B.S. from Boston College and Pre-Medical studies at Columbia University,
his M.D. from Yale Medical School and his M.B.A from Harvard Business School. He
is currently on the scientific advisory board of the National Tay Sachs and Allied Disease
Foundation.
Greg brings a proven track record of developing small biopharmaceutical companies and
making them successful to SSI Strategy.
|
